MPM

Leading Materials Testing Company Unveils Innovative Non-Destructive Testing Equipment

Retrieved on: 
Tuesday, October 18, 2022
Method, MPM, MP, Time, Hardness, Ultimate tensile strength, Electrode, I2S, Technology, Capital, Sun Capital Partners, Machine, Industry, Fracture, Steel, ASTM, Ageing, Direct stiffness method, Solution, Compliance, Ceramic

OKLAHOMA CITY, Oct. 18, 2022 /PRNewswire/ -- MP Machinery and Testing ("MPM"), a Praesidian Capital portfolio company, today announced the release of proprietary material testing equipment that non-destructively determines the material properties of in-service components and structures.

Key Points: 
  • OKLAHOMA CITY, Oct. 18, 2022 /PRNewswire/ -- MP Machinery and Testing ("MPM"), a Praesidian Capital portfolio company, today announced the release of proprietary material testing equipment that non-destructively determines the material properties of in-service components and structures.
  • MPM is a leading provider of advanced material testing products and services for the nuclear power & energy, steel, pipe, aerospace, defense, and transportation industries.
  • The testing equipment can also be modified for factory product line applications, laboratory applications, and failure analysis applications.
  • MPM offers testing services in the areas of material characterization, mechanical property measurement, failure analysis, corrosion testing, in-service component monitoring, and finite element analysis.

gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

Retrieved on: 
Wednesday, September 28, 2022
Cytokine release syndrome, OS, Safety, Nivolumab, HLA, Patient, Clinical trial, U.S. Securities and Exchange Commission, DLT, Nasdaq, CRS, Malignant transformation, Research, Large-cell lung carcinoma, Ipilimumab, PR, Risk, COVID-19, Ovary, Survival, NSCLC, Company, Growth, Cmax, Annual report, DCR, RECIST, Investor, DL, Cholangiocarcinoma, Ovarian cancer, Neoplasm, Population, MPM, Review, TCR, Progression-free survival, Tissue, Security (finance), GLOBE, Cancer, Infrared spectroscopy correlation table, Safety data sheet, Pancreatic cancer, Private Securities Litigation Reform Act, Therapy, Breast cancer, ORR, Metastasis, Cell, Cyber Safety Review Board, Secondary, Truc, PFS, Mesothelioma, Webcast, Pharmaceutical industry, Medical imaging, Vaccine

CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced positive topline results from the Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors, with some patients still being monitored for clinical response or stable disease.

Key Points: 
  • By BICR, the ORR was 21% among patients with malignant pleural/peritoneal mesothelioma (MPM) and 29% among those with ovarian cancer.
  • These are remarkable data in the context of solid tumors where there have been significant challenges with current CAR-T therapies.
  • The trial is enrolling patients with either mesothelin expressing non-small cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma, or malignant pleural/peritoneal mesothelioma (MPM).
  • Mesothelin is a cell-surface glycoprotein highly expressed in a wide range of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, pancreatic cancer and others.

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio

Retrieved on: 
Tuesday, September 13, 2022
Intas Biopharmaceuticals, Malignancy, Incidence, Mesothelioma, Ageing, Pemetrexed, Chest pain, Blistering, FDA, Solution, NSCLC, Vomiting, Population, MPM, Product, Lung cancer, Patient, Accord, Cancer, Technology, Heart, Research, Nausea, Fatigue, Chemotherapy, Pharmaceutical industry

DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs. The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.

Key Points: 
  • DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ --Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs.
  • The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.

BioImpact Capital Announces a Multi-Billion Dollar Landmark Transaction in Vaccines and Cancer

Retrieved on: 
Tuesday, August 16, 2022
Biotechnology, Health, Business, Finance, Other Health, Pharmaceutical, Asset Management, Professional Services, Oncology, Research, Infectious Diseases, General Health, Genetics, Science, FDA, Partner (business rank), Association, American Association, Cancer, Infection, Board, Research, History, MPM, Patient, Therapy, Vaccine, Biotechnology, OIF, RNA, Massachusetts Institute of Technology, Science, Initial public offering, American Association for Cancer Research, Circular RNA, RNA transfection, Pharmaceutical industry, Orna

Orna was created by MPM and BioImpact Capital in 2019, based on groundbreaking research from the Massachusetts Institute of Technology.

Key Points: 
  • Orna was created by MPM and BioImpact Capital in 2019, based on groundbreaking research from the Massachusetts Institute of Technology.
  • The company is focused on pioneering circular RNA, which can be used in multiple applications such as next generation vaccines.
  • BioImpact Capital is the investment manager of OIF as well as its successor fund, Oncology Impact Fund 2 (OIF 2).
  • BioImpact Capital is an affiliate of MPM Capital, which has shepherded more than 100 companies through IPOs and mergers and acquisitions.

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

Retrieved on: 
Tuesday, August 16, 2022
Biotechnology, Pharmaceutical, Health, MSD, LNP, U.S. Securities and Exchange Commission, Multimedia, Cell, NYSE, Technology, Annual general meeting, YouTube, SEC, Infection, Patent, Tissue, Society, Security (finance), Research, MPM, Patient, MRK, Gene, Instagram, Therapy, COVID-19, Twitter, Merck & Co., Vaccine, RNA, MIT, Coronavirus, News, Science, Lists of diseases, Private Securities Litigation Reform Act, LinkedIn, Animal, RNA transfection, Pharmaceutical industry, Facebook, Merck, Orna

Orna will retain rights to its oRNA-LNP technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease.

Key Points: 
  • Orna will retain rights to its oRNA-LNP technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease.
  • Ornas proprietary oRNA technology creates circular RNAs (oRNAs) from linear RNAs by self-circularization.
  • Our oRNA technology plus novel delivery solutions are designed to unlock the full potential of RNA in therapeutics and vaccines, said Tom Barnes, Chief Executive Officer of Orna.
  • The combined expertise of Orna and Merck aims to accelerate the development of RNA therapeutics for patients in need of better treatment options.

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Acute myeloid leukemia, Immortalised cell line, Advanced Materials and Processes Research Institute, WT1, SPD, GLOBE, NEW, Clinical trial, CT, IND, Research, AML, MPM, CDK9, Patient, Cancer, Pembrolizumab, Company, COVID-19, Lymphoma, D, Acquisition, NMPA, SD, Nivolumab, Safety, GPS, NASDAQ, Payment, Second, Ovarian cancer, Toxic epidermal necrolysis, Mesothelioma, SLS, Pharmaceutical industry

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2022.

Key Points: 
  • Financial Results for the Second Quarter 2022:
    Licensing revenue: There was no licensing revenue for the second quarter of 2022 and $1.0 million for the first half of 2022, which related to Chinas NMPA approval of an IND application by 3D Medicines.
  • This compares to $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021.
  • R&D Expenses: Research and development expenses for the second quarter of 2022 were $5.5 million, compared to $3.5 million for the same period in 2021.
  • Acquired In-Process Research and Development: There was no acquired in-process research and development for the second quarter of 2022.

TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Industry, CD70, GLOBE, Private Securities Litigation Reform Act, Cancer, Clinical trial, Investment, TCR, PD-1, IND, LLC, PD-L1, Cholangiocarcinoma, Financial management, Research, Annual report, Security (finance), HLA, MPM, NSCLC, Patient, Review, Therapy, COVID-19, Company, Cell, Large-cell lung carcinoma, Pancreatic cancer, D, Data, Partnership, Safety, Truc, Risk, Nasdaq, Ovarian cancer, Conference, Colorectal cancer, Pharmaceutical industry, Vaccine, Video game

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • Net cash used in operations was $19.5 million for the second quarter of 2022 compared to $15.0 million for the second quarter of 2021.
  • R&D Expenses: Research and development expenses were $25.8 million for the second quarter of 2022 compared to $18.6 million for the second quarter of 2021.
  • G&A Expenses: General and administrative expenses were $6.0 million for the second quarter of 2022 compared to $5.7 million for the second quarter of 2021.
  • Net Loss: Net loss was $31.6 million for the second quarter of 2022 compared to $24.3 million for the second quarter of 2021.

Renowned Biopharma Leaders Join Newly Established Kallyope Clinical Development Advisory Board

Retrieved on: 
Friday, August 5, 2022
Research, Neurology, Genetics, Biometrics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, FDA, Novartis, Internal medicine, CEO, European Medicines Agency, Leadership, Molecular biology, Novo Nordisk, United States Air Force Scientific Advisory Board, MPM, List of life sciences, Therapy, Infection, Bristol Myers Squibb, Nobel, Drug development, Pharmacia, Medicine, Ortho-McNeil Pharmaceutical, Schering-Plough, Physician, Merck & Co., Genetics, Bausch & Lomb, Melinta Therapeutics, Health, Vertex Pharmaceuticals, Pharmaceutical industry

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board.

Key Points: 
  • Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board.
  • As we expand into our next phase, we will be drawing on the wisdom and expertise of external leaders in clinical development.
  • All four of these leaders have initiated and guided development programs with far-reaching impact on global medicine.
  • Prior to joining MPM, Dr. Stoner was senior vice president of Global Clinical Development Operations at Merck Research Laboratories, where she was responsible for clinical development activities in more than 40 countries.

Fiddler Announces Giga-Scale Model Performance Management with Deeper Understanding of Unstructured Models and Fine Discoverability to Launch New AI Initiatives

Retrieved on: 
Thursday, July 28, 2022
Software, Technology, Artificial Intelligence, Data Management, MPM, Natural language processing, Time, View, Environment, 2009 Davis Cup, Insurance, Trust, Product management, Â, Address, CV, Data science, CEO, ML, Glass, Solution, Probability, Travel, UI, Bias, Language, NLP, Weather, Fortune 500, Organization, Machine learning, MLOps, Blog, Health, Engineering, XAI, AI, Founder, Medical device, Risk management, Fiddle

With these new features, the Fiddler MPM platform is delivering a deeper understanding of unstructured model behavior and performance, and enhanced scalability, discoverability of rare and nuanced model drifts, and ease of use.

Key Points: 
  • With these new features, the Fiddler MPM platform is delivering a deeper understanding of unstructured model behavior and performance, and enhanced scalability, discoverability of rare and nuanced model drifts, and ease of use.
  • Such steps include reducing bias (74%), tracking performance variations and model drift (68%), and making sure they can explain AI-powered decisions (61%).
  • To learn more about Fiddler, visit: www.fiddler.ai
    Fiddler is a pioneer in Model Performance Management for responsible AI.
  • Fortune 500 organizations use Fiddler across training and production models to accelerate AI time-to-value and scale, build trusted AI solutions, and increase revenue.

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

Retrieved on: 
Wednesday, June 22, 2022
Factor X, Cancer, Review, Association, FDA, TAZ, NF2, COVID-19, American Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biology, Tumor microenvironment, TEAD, Mesothelioma, Trial of the century, Research, Private Securities Litigation Reform Act, Fast Track, LinkedIn, RAS, Hippopotamus, EHE, MD, Bristol Myers Squibb, SEC, Radiation, Twitter, Food, Patient, MPM, Annual general meeting, GLOBE, Orphan drug, Immunotherapy, Pharmaceutical industry

Fast Track designation granted by FDA facilitates the development and expedites the review of drugs intended to treat serious or life-threatening diseases.

Key Points: 
  • Fast Track designation granted by FDA facilitates the development and expedites the review of drugs intended to treat serious or life-threatening diseases.
  • Features of Fast Track designation include opportunities for more frequent interactions with the FDA review team and, if supported by clinical data, the therapy could potentially be eligible for priority review.
  • Earlier in 2022, the FDA granted IK-930 Orphan Drug designation, which supports development of drugs for rare disorders, as a potential novel therapeutic option for patients with malignant pleural mesothelioma.
  • We are delighted to announce that IK-930 has been granted Fast Track designation, demonstrating the potential of IK-930 to address the unmet medical need of people with unresectable NF2-deficient MPM, said Sergio Santillana, MD, Chief Medical Officer at Ikena.